266 related articles for article (PubMed ID: 26891836)
1. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.
Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M
Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836
[TBL] [Abstract][Full Text] [Related]
2. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
3. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.
Pavey GJ; Qureshi AT; Tomasino AM; Honnold CL; Bishop DK; Agarwal S; Loder S; Levi B; Pacifici M; Iwamoto M; Potter BK; Davis TA; Forsberg JA
Bone; 2016 Sep; 90():159-67. PubMed ID: 27368930
[TBL] [Abstract][Full Text] [Related]
4. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
5. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
Elife; 2018 Sep; 7():. PubMed ID: 30226468
[TBL] [Abstract][Full Text] [Related]
6. Retinoid Agonists in the Targeting of Heterotopic Ossification.
Pignolo RJ; Pacifici M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831466
[TBL] [Abstract][Full Text] [Related]
7. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.
Pacifici M
Bone; 2018 Apr; 109():267-275. PubMed ID: 28826842
[TBL] [Abstract][Full Text] [Related]
8. Palovarotene inhibits connective tissue progenitor cell proliferation in a rat model of combat-related heterotopic ossification.
Wheatley BM; Cilwa KE; Dey D; Qureshi AT; Seavey JG; Tomasino AM; Sanders EM; Bova W; Boehm CA; Iwamoto M; Potter BK; Forsberg JA; Muschler GF; Davis TA
J Orthop Res; 2018 Apr; 36(4):1135-1144. PubMed ID: 28960501
[TBL] [Abstract][Full Text] [Related]
9. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
[TBL] [Abstract][Full Text] [Related]
10. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
[TBL] [Abstract][Full Text] [Related]
11. Palovarotene inhibits the NF-κB signalling pathway to prevent heterotopic ossification.
Huang J; Wu J; Lin J; Li C; Tang B; Xiao H
Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):881-892. PubMed ID: 35638441
[TBL] [Abstract][Full Text] [Related]
12. Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations.
Mundy C; Yao L; Shaughnessy KA; Saunders C; Shore EM; Koyama E; Pacifici M
JBMR Plus; 2023 Dec; 7(12):e10821. PubMed ID: 38130748
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ectopic bone formation by a selective retinoic acid receptor alpha-agonist: a new therapy for heterotopic ossification?
Shimono K; Morrison TN; Tung WE; Chandraratna RA; Williams JA; Iwamoto M; Pacifici M
J Orthop Res; 2010 Feb; 28(2):271-7. PubMed ID: 19725108
[TBL] [Abstract][Full Text] [Related]
14. Palovarotene: First Approval.
Hoy SM
Drugs; 2022 Apr; 82(6):711-716. PubMed ID: 35384641
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
Wentworth KL; Masharani U; Hsiao EC
Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
[TBL] [Abstract][Full Text] [Related]
16. Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP).
Lindborg CM; Brennan TA; Wang H; Kaplan FS; Pignolo RJ
Bone; 2018 Apr; 109():153-157. PubMed ID: 28963080
[TBL] [Abstract][Full Text] [Related]
17. Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
Goldhamer DJ; Lees-Shepard JB
Elife; 2019 Jan; 8():. PubMed ID: 30698142
[TBL] [Abstract][Full Text] [Related]
18. Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.
Matsuo K; Chavez RD; Barruet E; Hsiao EC
Curr Osteoporos Rep; 2019 Dec; 17(6):387-394. PubMed ID: 31721068
[TBL] [Abstract][Full Text] [Related]
19. Palovarotene Can Attenuate Heterotopic Ossification Induced by Tendon Stem Cells by Downregulating the Synergistic Effects of Smad and NF-
Huang J; Lin J; Li C; Tang B; Xiao H
Stem Cells Int; 2022; 2022():1560943. PubMed ID: 35530413
[TBL] [Abstract][Full Text] [Related]
20. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
